Last reviewed · How we verify
Docetaxel, mitotic inhibitor; intravenous
Docetaxel, mitotic inhibitor; intravenous is a Small molecule drug developed by Array Biopharma, now a wholly owned subsidiary of Pfizer. It is currently in Phase 1 development.
At a glance
| Generic name | Docetaxel, mitotic inhibitor; intravenous |
|---|---|
| Sponsor | Array Biopharma, now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (PHASE3)
- RegoNivo vs Standard of Care Chemotherapy in AGOC (PHASE3)
- A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel, mitotic inhibitor; intravenous CI brief — competitive landscape report
- Docetaxel, mitotic inhibitor; intravenous updates RSS · CI watch RSS
- Array Biopharma, now a wholly owned subsidiary of Pfizer portfolio CI
Frequently asked questions about Docetaxel, mitotic inhibitor; intravenous
What is Docetaxel, mitotic inhibitor; intravenous?
Docetaxel, mitotic inhibitor; intravenous is a Small molecule drug developed by Array Biopharma, now a wholly owned subsidiary of Pfizer.
Who makes Docetaxel, mitotic inhibitor; intravenous?
Docetaxel, mitotic inhibitor; intravenous is developed by Array Biopharma, now a wholly owned subsidiary of Pfizer (see full Array Biopharma, now a wholly owned subsidiary of Pfizer pipeline at /company/array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer).
What development phase is Docetaxel, mitotic inhibitor; intravenous in?
Docetaxel, mitotic inhibitor; intravenous is in Phase 1.